ArticleNPJ precision oncology2026
Development and validation of a multimodal AI-agent system for prognosis analysis of bladder urothelial carcinoma.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Precise survival risk stratification for bladder urothelial carcinoma (BUC) remains a clinical challenge. We developed and validated a multimodal AI agent that integrates textual, radiographic, and pathological data from 1185 patients across four medical centers to predict survival risk. The agent employs LLMs to standardize pathology reports, interactive deep learning networks for precise CT image segmentation, and extracts features from CT scans and whole slide images using CTVisionNet and MacroVisionNet. The multimodal fusion framework, MATCH-Net, integrates these features with microscopic pathology information and clinical text embeddings using a multi-head attention mechanism to generate a comprehensive prognostic score. In multi-center validation, MATCH-Net demonstrated robust performance (C-index ranging from 0.836 to 0.874) and effectively stratified patients into high- and low-risk groups, identifying potential candidates responsive to adjuvant chemotherapy. Furthermore, the framework enabled the quantification of novel, interpretable prognostic biomarkers and provides a reliable and clinically applicable solution for personalized BUC prognosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.